(Circulation. 1995;92:365-371.)
© 1995 American Heart Association, Inc.
Articles |
Synergistic Effect of Vascular Endothelial Growth Factor and Basic Fibroblast Growth Factor on Angiogenesis In Vivo
From the Departments of Medicine (Cardiology), Surgery (Cardiovascular), and Biomedical Research, St Elizabeth's Medical Center, Tufts University School of Medicine, Boston Mass (T.A., C.B., L.P.Z., S.T., J.F.S.), and the Department of Cardiovascular Research, Genentech Inc (S.B., N.F., J.M.I.), South San Francisco, Calif.
Correspondence to James F. Symes, MD, St Elizabeth's Medical Center, Medical Office Building, 11 Nevins St, Suite #306, Boston, MA 02135.
Background Recent studies have suggested that vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF) may have synergistic effects on the induction of angiogenesis in vitro. Therefore, we investigated the hypothesis that the simultaneous administration of VEGF and bFGF, each having been previously shown to independently enhance collateral development in an animal model of hind limb ischemia, could have a synergistic effect in vivo.
Methods and Results Ten days after surgical induction of unilateral hind limb ischemia, New Zealand White rabbits were randomized to receive either VEGF 500 µg alone (n=6), bFGF 10 µg alone (n=7), VEGF 500 µg, immediately followed by 10 µg bFGF (n=7), or vehicle only (control animals, n=8) in each case administered intra-arterially via a catheter in the internal iliac artery of the ischemic limb. BP ratio (BPR, ischemic/healthy limb) at day 10 for the VEGF+bFGF group was 0.82±0.01, much superior (P<.0005) to that of either the VEGF group (0.52±0.02) or the bFGF group (0.57±0.02). This outcome persisted at day 30: BPR in the VEGF+bFGF group (0.91±0.02) exceeded that of the control group (0.49±0.05, P<.0001), the VEGF group (0.65±0.03, P<.0005), or the bFGF group (0.66±0.03, P<.0005). Serial angiography demonstrated a progressive increase in luminal diameter of the stem collateral artery and the number of opacified collaterals in the thigh of the ischemic limbs in all groups. Stem artery diameter with VEGF+bFGF (1.34±0.07 mm) on day 30 was significantly (P<.05) greater than with either VEGF (1.09±0.09) or bFGF (1.18±0.06) alone. Capillary density was significantly greater (P<.05) in VEGF+bFGF animals (275±20 mm2) compared with VEGF (201±8) or bFGF (209±15).
Conclusions Combined administration of VEGF and bFGF stimulates significantly greater and more rapid augmentation of collateral circulation, resulting in superior hemodynamic improvement compared with either VEGF or bFGF alone. This synergism of two angiogenic mitogens with different target cell specificities may have important implications for the treatment of severe arterial insufficiency in patients whose disease is not amenable to direct revascularization.
Key Words: growth substances • ischemia
This article has been cited by other articles:
 |
|
 |
|
  K. J Woad, A. J Hammond, M. Hunter, G. E Mann, M. G Hunter, and R. S Robinson FGF2 is crucial for the development of bovine luteal endothelial networks in vitro Reproduction, September 1, 2009; 138(3): 581 - 588. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C Kalka and I. Baumgartner Gene and stem cell therapy in peripheral arterial occlusive disease Vascular Medicine, May 1, 2008; 13(2): 157 - 172. [Abstract] [PDF]
|
|
|
|
 |
|
 P. Uttayarat, M. Chen, M. Li, F. D. Allen, R. J. Composto, and P. I. Lelkes Microtopography and flow modulate the direction of endothelial cell migration Am J Physiol Heart Circ Physiol, February 1, 2008; 294(2): H1027 - H1035. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. C. White, K. J. Lavine, and D. M. Ornitz FGF9 and SHH regulate mesenchymal Vegfa expression and development of the pulmonary capillary network Development, October 15, 2007; 134(20): 3743 - 3752. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S.-W. Cho, I.-K. Kim, S. H. Bhang, B. Joung, Y. J. Kim, K. J. Yoo, Y.-S. Yang, C. Y. Choi, and B.-S. Kim Combined therapy with human cord blood cell transplantation and basic fibroblast growth factor delivery for treatment of myocardial infarction Eur J Heart Fail, October 1, 2007; 9(10): 974 - 985. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J.-P. Dolle, A. Rezvan, F. D. Allen, P. Lazarovici, and P. I. Lelkes Nerve Growth Factor-Induced Migration of Endothelial Cells J. Pharmacol. Exp. Ther., December 1, 2005; 315(3): 1220 - 1227. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Heinl-Green, P. W. Radke, F. M. Munkonge, O. Frass, J. Zhu, K. Vincent, D. M. Geddes, and E. W.F.W. Alton The efficacy of a 'master switch gene' HIF-1{alpha} in a porcine model of chronic myocardial ischaemia Eur. Heart J., July 1, 2005; 26(13): 1327 - 1332. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. D. Nandini, T. Mikami, M. Ohta, N. Itoh, F. Akiyama-Nambu, and K. Sugahara Structural and Functional Characterization of Oversulfated Chondroitin Sulfate/Dermatan Sulfate Hybrid Chains from the Notochord of Hagfish: NEURITOGENIC AND BINDING ACTIVITIES FOR GROWTH FACTORS AND NEUROTROPHIC FACTORS J. Biol. Chem., December 3, 2004; 279(49): 50799 - 50809. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Kinnaird, E. Stabile, M. S. Burnett, and S. E. Epstein Bone Marrow-Derived Cells for Enhancing Collateral Development: Mechanisms, Animal Data, and Initial Clinical Experiences Circ. Res., August 20, 2004; 95(4): 354 - 363. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Kinnaird, E. Stabile, M.S. Burnett, M. Shou, C.W. Lee, S. Barr, S. Fuchs, and S.E. Epstein Local Delivery of Marrow-Derived Stromal Cells Augments Collateral Perfusion Through Paracrine Mechanisms Circulation, March 30, 2004; 109(12): 1543 - 1549. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Kinnaird, E. Stabile, M.S. Burnett, C.W. Lee, S. Barr, S. Fuchs, and S.E. Epstein Marrow-Derived Stromal Cells Express Genes Encoding a Broad Spectrum of Arteriogenic Cytokines and Promote In Vitro and In Vivo Arteriogenesis Through Paracrine Mechanisms Circ. Res., March 19, 2004; 94(5): 678 - 685. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Kondoh, H. Koyama, T. Miyata, T. Takato, H. Hamada, and H. Shigematsu Conduction performance of collateral vessels induced by vascular endothelial growth factor or basic fibroblast growth factor Cardiovasc Res, January 1, 2004; 61(1): 132 - 142. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Zilberberg, S. Shinkaruk, O. Lequin, B. Rousseau, M. Hagedorn, F. Costa, D. Caronzolo, M. Balke, X. Canron, O. Convert, et al. Structure and Inhibitory Effects on Angiogenesis and Tumor Development of a New Vascular Endothelial Growth Inhibitor J. Biol. Chem., September 12, 2003; 278(37): 35564 - 35573. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Garofalo, E. Naumova, L. Manenti, C. Ghilardi, G. Ghisleni, M. Caniatti, T. Colombo, J. M. Cherrington, E. Scanziani, M. I. Nicoletti, et al. The Combination of the Tyrosine Kinase Receptor Inhibitor SU6668 with Paclitaxel Affects Ascites Formation and Tumor Spread in Ovarian Carcinoma Xenografts Growing Orthotopically Clin. Cancer Res., August 1, 2003; 9(9): 3476 - 3485. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Lavie, H. Kraiczi, A. Hefetz, H. Ghandour, A. Perelman, J. Hedner, and P. Lavie Plasma Vascular Endothelial Growth Factor in Sleep Apnea Syndrome: Effects of Nasal Continuous Positive Air Pressure Treatment Am. J. Respir. Crit. Care Med., June 15, 2002; 165(12): 1624 - 1628. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. De Marchis, D. Ribatti, C. Giampietri, A. Lentini, D. Faraone, M. Scoccianti, M. C. Capogrossi, and A. Facchiano Platelet-derived growth factor inhibits basic fibroblast growth factor angiogenic properties in vitro and in vivo through its alpha receptor Blood, March 15, 2002; 99(6): 2045 - 2053. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. M. Olfert, E. C. Breen, O. Mathieu-Costello, and P. D. Wagner Skeletal muscle capillarity and angiogenic mRNA levels after exercise training in normoxia and chronic hypoxia J Appl Physiol, September 1, 2001; 91(3): 1176 - 1184. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Neben, T. Moehler, G. Egerer, A. Kraemer, J. Hillengass, A. Benner, A. D. Ho, and H. Goldschmidt High Plasma Basic Fibroblast Growth Factor Concentration Is Associated with Response to Thalidomide in Progressive Multiple Myeloma Clin. Cancer Res., September 1, 2001; 7(9): 2675 - 2681. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. K. Ruohola, T. P. Viitanen, E. M. Valve, J. A. Seppänen, N. T. Loponen, J. J. Keskitalo, P. T. Lakkakorpi, and P. L. Härkönen Enhanced Invasion and Tumor Growth of Fibroblast Growth Factor 8b-overexpressing MCF-7 Human Breast Cancer Cells Cancer Res., May 1, 2001; 61(10): 4229 - 4237. [Abstract] [Full Text]
|
|
|
|
 |
|
 R. K. Dubey and E. K. Jackson Estrogen-induced cardiorenal protection: potential cellular, biochemical, and molecular mechanisms Am J Physiol Renal Physiol, March 1, 2001; 280(3): F365 - F388. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. T.-P. Poon, S.-T. Fan, and J. Wong Clinical Implications of Circulating Angiogenic Factors in Cancer Patients J. Clin. Oncol., February 15, 2001; 19(4): 1207 - 1225. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Robinson and S. Stringer The splice variants of vascular endothelial growth factor (VEGF) and their receptors J. Cell Sci., January 3, 2001; 114(5): 853 - 865. [Abstract] [PDF]
|
|
|
|
|
|
R. Giavazzi, R. Giuliani, D. Coltrini, M. R. Bani, C. Ferri, B. Sennino, M. P. M. Tosatti, A. Stoppacciaro, and M. Presta Modulation of Tumor Angiogenesis by Conditional Expression of Fibroblast Growth Factor-2 Affects Early but not Established Tumors Cancer Res., January 1, 2001; 61(1): 309 - 317. [Abstract] [Full Text]
|
|
|
|
|
|
E. L. Lund, C. Thorsen, M. W. B. Pedersen, N. Junker, and P. E. G. Kristjansen Relationship Between Vessel Density and Expression of Vascular Endothelial Growth Factor and Basic Fibroblast Growth Factor in Small Cell Lung Cancer in Vivo and in Vitro Clin. Cancer Res., November 1, 2000; 6(11): 4287 - 4291. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. K. Rofstad and E. F. Halsør Vascular Endothelial Growth Factor, Interleukin 8, Platelet-derived Endothelial Cell Growth Factor, and Basic Fibroblast Growth Factor Promote Angiogenesis and Metastasis in Human Melanoma Xenografts Cancer Res., September 1, 2000; 60(17): 4932 - 4938. [Abstract] [Full Text]
|
|
|
|
 |
|
 A. Otani, H. Takagi, H. Oh, S. Koyama, M. Matsumura, and Y. Honda Expressions of Angiopoietins and Tie2 in Human Choroidal Neovascular Membranes Invest. Ophthalmol. Vis. Sci., August 1, 1999; 40(9): 1912 - 1920. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. J. Laham, M. Rezaee, M. Post, F. W. Sellke, R. A. Braeckman, D. Hung, and M. Simons Intracoronary and Intravenous Administration of Basic Fibroblast Growth Factor: Myocardial and Tissue Distribution Drug Metab. Dispos., July 1, 1999; 27(7): 821 - 826. [Abstract] [Full Text]
|
|
|
|
 |
|
 G. Neufeld, T. Cohen, S. Gengrinovitch, and Z. Poltorak Vascular endothelial growth factor (VEGF) and its receptors FASEB J, January 1, 1999; 13(1): 9 - 22. [Abstract] [Full Text]
|
|
|
|
 |
|
 F. W. Sellke, R. J. Laham, E. R. Edelman, J. D. Pearlman, and M. Simons Therapeutic Angiogenesis With Basic Fibroblast Growth Factor: Technique and Early Results Ann. Thorac. Surg., June 1, 1998; 65(6): 1540 - 1544. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. K.W. Hsu, Y. Guo, G. F. Alberts, N. G. Copeland, D. J. Gilbert, N. A. Jenkins, K. A. Peifley, and J. A. Winkles Identification of a Murine TEF-1-related Gene Expressed after Mitogenic Stimulation of Quiescent Fibroblasts and during Myogenic Differentiation J. Biol. Chem., June 7, 1996; 271(23): 13786 - 13795. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Leali, M. Belleri, C. Urbinati, D. Coltrini, P. Oreste, G. Zoppetti, D. Ribatti, M. Rusnati, and M. Presta Fibroblast Growth Factor-2 Antagonist Activity and Angiostatic Capacity of Sulfated Escherichia coli K5 Polysaccharide Derivatives J. Biol. Chem., October 5, 2001; 276(41): 37900 - 37908. [Abstract] [Full Text] [PDF]
|
|